ALLO May 2023 12.500 put
| Previous close | 6.60 |
| Open | 6.60 |
| Bid | 3.90 |
| Ask | 5.80 |
| Strike | 12.50 |
| Expiry date | 2023-05-19 |
| Day's range | 6.60 - 6.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
- Zacks
Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 Weeks
The heavy selling pressure might have exhausted for Allogene Therapeutics (ALLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Zacks
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate GovernanceSOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its 2022 annual ESG report. The report provides an update on the Company’s robust efforts to r
